Nevertheless, in light of recent findings that right-sided RAS and RAF wild-type tumors do not respond well to anti-EGFR therapies [55], there is an emerging question regarding whether anti-EGFR therapy should be given only to liver metastasis originating from left-sided CRC. Here, EGFR is linked to colorectal carcinoma.